文献速递肝病消化道肿瘤与早癌

直接抗病毒治疗与肝细胞癌复发无关:一项多中心北美队列研究

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
PubMed 文献 · Gastroenterology · 2019-01-18

该回顾性队列研究纳入2013年1月至2017年12月美国和加拿大31个医疗系统内对肝细胞癌治疗达完全缓解的丙型肝炎病毒相关肝细胞癌患者,比较接受与未接受直接抗病毒治疗者的复发模式。结果显示直接抗病毒治疗与肝细胞癌复发(风险比0.90,95%可信区间0.70-1.16)或早期复发(风险比0.96,95%可信区间0.70-1.34)均无关。

要点

  • 直接抗病毒治疗与肝细胞癌总体复发无关,风险比0.90(95%可信区间0.70-1.16)。
  • 直接抗病毒治疗与早期肝细胞癌复发无关,风险比0.96(95%可信区间0.70-1.34)。
  • 两组复发模式相似,多数复发位于米兰标准内(74.2% vs 78.8%,P=0.23)。

核心结论

  • 在北美对肝细胞癌治疗达完全缓解的大队列中,直接抗病毒治疗与肝细胞癌总体或早期复发增加无关,复发模式包括治疗反应在治疗与未治疗患者中相似。

研究设计与样本

  • 回顾性队列研究,纳入2013年1月至2017年12月美国和加拿大31个医疗系统内丙型肝炎病毒相关肝细胞癌且对切除、局部消融、经动脉化疗或放射栓塞、或放疗达完全缓解的患者共793例。
  • 304例(38.3%)接受直接抗病毒治疗,489例(61.7%)未治疗;采用Cox回归分析直接抗病毒治疗与完全缓解后至复发时间的关联,直接抗病毒治疗作为时变暴露分析。

主要发现

  • 直接抗病毒治疗组128例(42.1%)复发,其中早期复发52例;未治疗组288例(58.9%)复发,其中早期复发227例。
  • 调整研究中心、年龄、性别、Child-Pugh评分、甲胎蛋白水平、肿瘤负荷和肝细胞癌治疗方式后,直接抗病毒治疗与肝细胞癌复发无关(风险比0.90,95%可信区间0.70-1.16),与早期肝细胞癌复发也无关(风险比0.96,95%可信区间0.70-1.34)。
  • 直接抗病毒治疗组与未治疗组多数复发位于米兰标准内(74.2% vs 78.8%,P=0.23)。
  • 直接抗病毒治疗组较未治疗组更多患者接受复发性肝细胞癌的潜在治愈性治疗(32.0% vs 24.6%)并获得完全或部分缓解(45.3% vs 41.0%),但未达统计学显著。

关键数值与推荐

  • 早期肝细胞癌复发定义为完全缓解后365天内复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort. METHODS: We conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy from January 2013 through December 2017 at 31 health systems throughout the United States and Canada. Cox regression was used to examine the association between DAA therapy and time to recurrence after a complete response, with DAA therapy analyzed as a time-varying exposure. We also estimated the association between DAA therapy and risk of early HCC recurrence (defined as 365 days after complete response). RESULTS: Of 793 patients with HCV-associated HCC, 304 (38.3%) received DAA therapy and 489 (61.7%) were untreated. HCC recurred in 128 DAA-treated patients (42.1%; early recurrence in 52 patients) and 288 untreated patients (58.9%; early recurrence in 227 patients). DAA therapy was not associated with HCC recurrence (hazard ratio 0.90, 95% confidence interval 0.70-1.16) or early HCC recurrence (hazard ratio 0.96, 95% confidence interval 0.70-1.34) after we adjusted for study site, age, sex, Child-Pugh score, α-fetoprotein level, tumor burden, and HCC treatment modality. In DAA-treated and untreated patients, most recurrences were within the Milan criteria (74.2% vs 78.8%; P = .23). A larger proportion of DAA-treated than untreated patients received potentially curative HCC therapy for recurrent HCC (32.0% vs 24.6%) and achieved a complete or partial response (45.3% vs 41.0%) but this did not achieve statistical significance. CONCLUSION: In a large cohort of North American patients with complete response to HCC treatment, DAA therapy was not associated with increased overall or early HCC recurrence. HCC recurrence patterns, including treatment response, were similar in DAA-treated and untreated patients.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019. PMID: 30660729. doi:10.1053/j.gastro.2019.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。